Consolidated Statement of Changes in Temporary Equity and StockHolders' Deficiency (Parenthetical) |
12 Months Ended |
|---|---|
|
Dec. 31, 2021
USD ($)
| |
| Subsidiary, Sale of Stock [Line Items] | |
| Common stock issued for cash, net of offering costs | $ 4,177,400 |
| Cash payments for offering costs | 319,684 |
| Underwriter [Member] | |
| Subsidiary, Sale of Stock [Line Items] | |
| Gross proceeds from public offering | 8,002,004 |
| Professional fees | 715,000 |
| Common stock issued for cash, net of offering costs | 364,979 |
| Cash payments for offering costs | 319,684 |
| Private Placement [Member] | |
| Subsidiary, Sale of Stock [Line Items] | |
| Gross proceeds from public offering | 5,135,210 |
| Common stock issued for cash, net of offering costs | 500,000 |
| Commission paid | $ 457,810 |
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Cash payments for offering costs. No definition available.
|
| X | ||||||||||
- Definition The amount of cash paid for commissions during the current period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|